Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs placebo (PBO) after radical resection for high-risk muscle-invasive urothelial carcinoma (MIUC): results from the phase 3 CheckMate 274 trialep138
Document type:
Meeting Abstract
Author(s):
Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; Witjes, J. A.